Content deleted Content added
m Remove redundant parameters InChI, InChIKey (StdInChI, StdInChIKey are used). See Talk (via AWB script) |
No edit summary |
||
Line 27: | Line 27: | ||
| ATC_prefix = |
| ATC_prefix = |
||
| ATC_suffix = |
| ATC_suffix = |
||
| PubChem = |
| PubChem = 86273676 |
||
| ChemSpiderID = |
| ChemSpiderID = |
||
| smiles = CCCCCN1N=C(C(=O)NC(C)(C)C2=CC=CC=C2)C2=CC=CC=C12 |
| smiles = CCCCCN1N=C(C(=O)NC(C)(C)C2=CC=CC=C2)C2=CC=CC=C12 |
Revision as of 07:52, 3 June 2016
Legal status | |
---|---|
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
Chemical and physical data | |
Formula | C22H27N3O |
Molar mass | 349.5 g/mol g·mol−1 |
3D model (JSmol) | |
| |
|
CUMYL-PINACA (also known as SGT-24) is an indazole-3-carboxamide based synthetic cannabinoid. CUMYL-PINACA acts as a potent agonist for the cannabinoid receptors, with approximately 3x selectivity for CB1, having an EC50 of 0.15nM for human CB1 receptors and 0.41nM for human CB2 receptors.[1]
Legal status
Sweden's public health agency suggested to classify CUMYL-PINACA as hazardous substance on November 10, 2014.[2]
See also
References
- ^ Bowden; et al. (11 April 2013). "Patent WO 2014167530 - Cannabinoid compounds". New Zealand Patent application 623626. Retrieved 11 July 2015.
- ^ "Cannabinoider föreslås bli klassade som hälsofarlig vara". Retrieved 11 July 2015.